The FY2025 (Dec) proxy of Relay Therapeutics names 22 peer companies for pay. Among Relay Therapeutics and these peers, CEO pay was 11th highest of 13 and total shareholder return was 9th highest of 12.
11th highest of 13in Relay Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$2.8M$27.8M
9th highest of 12in Relay Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$14$414
Pay peer group, FY2025 (Dec) proxy
| Cogent Biosciences | ||
| BridgeBio Pharma | ||
| Arcus Biosciences | ||
| Kymera Therapeutics | ||
| Vir Biotechnology | ||
| CRISPR Therapeutics AG | ||
| Arvinas | ||
| Beam Therapeutics | ||
| Intellia Therapeutics | ||
| Denali Therapeutics | ||
| Schrodinger | ||
| Tango Therapeutics | Not disclosed | |
| Alector, Inc. | Not disclosed | Not disclosed |
| Allogene Therapeutics, Inc. | Not disclosed | Not disclosed |
| Editas Medicine, Inc. | Not disclosed | Not disclosed |
| Erasca | Not disclosed | Not disclosed |
| IGM Biosciences, Inc. | Not disclosed | Not disclosed |
| Iovance Biotherapeutics | Not disclosed | Not disclosed |
| Recursion Pharmaceuticals | Not disclosed | Not disclosed |
| Sana Biotechnology | Not disclosed | Not disclosed |
| SpringWorks Therapeutics, Inc. | Not disclosed | Not disclosed |
| Zentalis Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
22 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.